Elanco Animal Health (Elanco Animal Health) LT-Debt-to-Total-Asset : 0.40 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Elanco Animal Health's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.40.

Elanco Animal Health's long-term debt to total assets ratio increased from Dec. 2022 (0.35) to Dec. 2023 (0.40). It may suggest that Elanco Animal Health is progressively becoming more dependent on debt to grow their business.

Elanco Animal Health LT-Debt-to-Total-Asset Historical Data

The historical data trend for Elanco Animal Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health LT-Debt-to-Total-Asset Chart

Elanco Animal Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.26

0.32

0.37

0.35

0.40

Elanco Animal Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.36	0.38	0.41	0.40

Elanco Animal Health LT-Debt-to-Total-Asset Calculation

Elanco Animal Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	5736	/	14362
	=	0.40

Elanco Animal Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	5736	/	14362
	=	0.40

Elanco Animal Health (NYSE:ELAN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Elanco Animal Health LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanco Animal Health (Elanco Animal Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

5EA:Germany

Address

2500 Innovation Way, Greenfield, IN, USA, 46140

Website

https://www.elanco.com

Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Executives

Grace Mcardle	officer: EVP, MANUFACTURING AND QUALITY	2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington	officer: See remarks	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
R David Hoover	director	C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Jeffrey N Simmons	director, officer: Pres., Chief Executive Officer	2500 INNOVATION WAY, GREENFIELD IN 46140
John P Bilbrey	director
Rajeev A. Modi	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen	director	C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Michael J Harrington	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Brabander Ellen De	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger	officer: Ex VP, Gen Counsel & Corp Sec	C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia	director	11690 N.W. 105TH STREET, MIAMI FL 33178
William F Doyle	director
Uncas Gp Llc	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019